Facebook
X
LinkedIn
ForwardJanuary 29th, 2026: Emerging Therapeutic Agents for MASLD
Welcome to the second session of this ECHO program!
Claiming Credit
Thank you for attending the session on January 29, 2026. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to claim your credit on the following page
Target Audience
This ECHO® series is designed for a primary care audience. It is open to physicians, nurse practitioners (NPs), physician associates (PAs), and nurses who care for people with MASLD/MASH.
Learning Objectives:
At the conclusion of this learning activity, participants will be better able to:
- Define the conditions of MASLD and MASH and their relationship to cardiometabolic conditions such as obesity and type 2 diabetes.
- Integrate available non-invasive tests into clinical practice for the identification, risk-stratification, and monitoring of patients with MASLD/MASH.
- Identify emerging treatments for MASLD/MASH and the criteria for patient eligibility.
- Outline evidence-based management strategies for individuals with MASLD/MASH, including how available therapies (e.g., GLP-1 RAs) can target multiple disease mechanisms.
Grantor Acknowledgement:
This activity is supported by an educational grant from Novo Nordisk Inc.
Meena B. Bansal, MD, FAASLD
Professor of Medicine
System Chief, Division of Liver Diseases
Director, MASLD/MASH Center of Excellence
Icahn School of Medicine at Mount Sinai, New York, New York
Dr. Bansal has been on faculty at Mount Sinai since 2001. In addition to maintaining an NIH funded research program focused on molecular mechanism of liver fibrosis with seminal contributions to our understanding of liver fibrosis in people living with HIV, Dr. Bansal held many different leadership roles at Mount Sinai, including Transplant Hepatology Fellowship Director, Director of Translational Research, Medical Director of Hospital-Based Clinics, Chief Medical Officer of Mount Sinai Care, LLC, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President of Population Health for Quality and Efficiency. In these latter roles, she helped generate increased quality dollars in value-based contracts, created Mount Sinai’s first ambulatory pharmacy program and addressed broad population health needs. She has also served as the principal investigator for numerous clinical trials for MASH/NASH. At the international/national levels, she held the position of Secretary for the American Association for the Study of Liver and currently serves as the Director of the newly formed MASLD/MASH (NAFLD/NASH) Center of Excellence at Mount Sinai. In January 2024, Dr. Bansal was named System Chief, Division of Liver Diseases for the Mount Sinai Health System.
Dr. Bansal has received Grant Support from NIH, CDC/NIOSH, Pfizer, The Kinetix Group, Histoindex, Siemens and has served as a consultant for The Kinetix Group, Madrigal, Pfizer, Fibronostics, NOVO Nordisk, GSK, Boston Pharma, Merck, and Boeheringer-Ingelheim, CurveBio, and mBIOTA.
Disclosure Policy:
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Accreditation Statement
This activity is developed by Boston University Chobanian & Avedisian School of Medicine.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note that 4.0 credits are based on participation in all four ECHO® sessions.
Family Practitioner Accreditation
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
Please note that 4.0 credits are based on participation in all four ECHO® sessions.
Nurse Accreditation
Nursing Contact Hours: 4.0, of which 4.0 are eligible for pharmacology credit.
Please note that 4.0 credits are based on participation in all four ECHO® sessions.
Physician Associate Accreditation
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Please note that 4.0 credits are based on participation in all four ECHO® sessions.
Questions: If you have any questions about the program, registering or claiming credit please write [email protected] and your questions will be answered.
Available Credit
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 Participation